Use of carripiycin in mycobacterium tuberculosis infecti0n resistance

LAP599AUndetermined Publication Date: 2026-01-16SHENYANG FUYANG PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP599
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-12-31
Filing Date
2016-05-12
Publication Date
2026-01-16

AI Technical Summary

Technical Problem

Existing anti-tuberculosis drugs have many adverse reactions, long course of treatment, low cure rate and drug resistance, making it difficult to effectively treat tuberculosis, especially multi-drug-resistant strains.

Method used

A new 16-membered ring macrolide antibiotic corimycin was developed, which inhibits protein synthesis by binding to bacterial ribosomes. The activity of clinically isolated Mycobacterium tuberculosis was tested to demonstrate its effectiveness against drug-resistant Mycobacterium tuberculosis. property, and provides a composition composed of corimycin and a pharmaceutically acceptable carrier for use in preparing anti-tuberculosis infection drugs.

Benefits of technology

Clorimycin showed activity against 71.66% of 240 clinically isolated strains of Mycobacterium tuberculosis, which is better than some first-line drugs isoniazid and rifampicin. It has potential immunomodulatory effects and good tissue penetration, showing for potential use in the treatment of drug-resistant Mycobacterium tuberculosis infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure P%2F599_DRAWING_001
    Figure P%2F599_DRAWING_001
  • Figure P%2F599_DRAWING_002
    Figure P%2F599_DRAWING_002
Patent Text Reader

Abstract

Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.
Need to check novelty before this filing date? Find Prior Art

Description

Application of Keli mycin in anti - Mycobacterium tuberculosis infection Technical Field: The present invention relates to the application of macrolide antibiotics in the treatment of Mycobacterium tuberculosis infection. Technical Background: Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis (MTB) infection, mainly affecting the lungs, and it is the disease that causes the largest number of single deaths among infectious diseases. Tuberculosis is common in people with low immune function and is also the most common opportunistic infectious disease associated with AIDS. According to the report of the World Health Organization (WHO), there are 8 million - 10 million new cases of pulmonary tuberculosis worldwide every year, and 3 million - 4 million people die from tuberculosis, especially in developing countries. Another prediction shows that about 1 billion people will be infected and 35 million people will die from tuberculosis between 2000 and 2020. At the same time, the drug resistance of MTB increases year by year, which will become a major threat to global tuberculosis control. China is one of the 22 countries with a high incidence of tuberculosis in the world. The number of active tuberculosis patients ranks second in the world, and the epidemic characteristics show a high infection rate, high prevalence rate, high drug - resistance rate and high mortality rate. Among the 2 million MTB - positive patients in the country, more than 1 / 4 are drug - resistant Mycobacterium tuberculosis patients. Currently, the first - line drugs (with definite anti - Mycobacterium tuberculosis activity) commonly used in clinical treatment of tuberculosis are: rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide, etc. However, these drugs have many adverse reactions, limited bactericidal effect, and a long treatment course, usually more than 6 months, and the patient compliance is poor. The second - line anti - tuberculosis drugs (with bacteriostatic effect on Mycobacterium tuberculosis) are: capreomycin, ethionamide, para - aminosalicylic acid, cycloserine, ciprofloxacin, amikacin and kanamycin, etc. And these drugs have greater adverse reactions, a longer treatment time (18 - 24 months), high cost, and a lower cure rate. It is worth noting that clinical studies have shown that all first - line anti - tuberculosis drugs can cause damage to the liver. For example, the adverse reactions of isoniazid are peripheral neuritis, hepatotoxicity, central nervous system disorders and allergic reactions; the adverse reactions of rifampicin are hepatotoxicity, gastrointestinal discomfort, nervous system symptoms and allergic reactions; the main adverse reaction of ethambutol is optic nerve toxicity; the adverse reaction of pyrazinamide is skin jaundice and increased blood uric acid; the toxicity and bacterial drug resistance problems of streptomycin severely limit its application. Because it can reduce the incidence of bacterial drug resistance when combined with other drugs, although its clinical application is not much, it is still used as a first - line drug for anti - tuberculosis. [Zhu Shanmei Strait Pharmaceutical Journal 2010, 22(2): 123 - 125]. Another report shows that in 2010, the study of 518 clinically isolated Mycobacterium tuberculosis strains showed that Among the first-line drugs, the highest resistance rate to isoniazid reached 53.67%, and the resistance rate to streptomycin was 45.95%; among the second-line drugs, the resistance rate to ofloxacin was 39.77%, the resistance rate to amikacin was 15.83%, and the resistance rate to capreomycin was 21.81%; among the 321 strains resistant to one or more first-line drugs, the resistance rate to ofloxacin was as high as 57.01%, and the resistance rates to amikacin and capreomycin were 25.55% and 33.02% respectively; among the 217 multi-drug resistant strains, the resistance rate to ofloxacin reached 72.35% [Liu Yidian et al. Proceedings of the 2010 Clinical Basic Professional Academic Conference of the Chinese Anti-Tuberculosis Association, pp. 274-275]. This poses a severe challenge to the implementation of tuberculosis control work in China, especially the control of multi-drug resistant tuberculosis. Therefore, it is urgent to find alternative products against Mycobacterium tuberculosis, especially against multi-drug resistant strains. The new macrolide drugs clarithromycin, azithromycin, and roxithromycin are derivatives of the 14-membered ring erythromycin. Their antibacterial mechanism is different from that of the above-mentioned first-line and second-line anti-tuberculosis drugs. They reversibly bind to the 50S subunit of ribosomes in bacteria and interfere with protein synthesis. There are reports in China that the MIC of clarithromycin against sensitive Mycobacterium tuberculosis is 0.25 - 2.0 μg / ml, and the MIC against drug-resistant bacteria is 2.0 - 32 μg / ml; the MIC of azithromycin against Mycobacterium tuberculosis is 128 μg / ml [Tang Shenjie, The latest progress in anti-tuberculosis drug research, Chinese Journal of Antituberculosis, 2006, Vol. 28, Supplement, pp. 1-3]. According to foreign reports, the MIC of clarithromycin against M. tuberculosis H37Rv (ATCC 27294) is 6 μg / ml; the MIC of azithromycin is 95 μg / ml [Kanakeshwari Falzari et al: In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob. Agents and Chemother. 2005, 49(4): 1447-1454]; the MIC of roxithromycin ≥ 64 μg / ml. These drugs have not been included in the drugs for clinical treatment of Mycobacterium tuberculosis infection, but there are reports of their clinical use alone or in combination with anti-tuberculosis drugs for the treatment of multi-drug resistant tuberculosis infection diseases [Xu Li et al. Investigation on the use of anti-tuberculosis related antibacterial drugs in inpatients in Shenzhen. Chinese Journal of Antituberculosis 2010, 32(3): 151-154]. Studies have shown that 16-membered ring and 14-membered ring macrolide antibiotics have similar antibacterial mechanisms. Such drugs have low activity against Mycobacterium tuberculosis. For example, for M. tuberculosis H37Rv (ATCC 27294), the MIC of tylosin is 58.6 μg / ml, and the MICs of spiramycin and midecamycin are both >100 μg / ml [Kanakeshwari Falzari et al: In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob. Agents and Chemother. 2005, 49(4):1447-1454]. Therefore, to date, there have been no reports on the use of such antibiotics for the clinical treatment of tuberculosis at home and abroad. A new type of 16-membered ring macrolide antibiotic developed by our laboratory - colimycin (formerly known as shengji mycin, bitespiramycin), is a 4”-acylated spiramycin with josamycin as the main component. Its mechanism of action is to inhibit protein synthesis by binding to bacterial ribosomes. The results of in vitro and in vivo tests show that colimycin is effective against Gram-positive bacteria, especially some drug-resistant bacteria (such as β-lactam-resistant Staphylococcus aureus, erythromycin-resistant Staphylococcus aureus, etc.), and there is no obvious cross-resistance with similar drugs. At the same time, it has good antibacterial activity against mycoplasma and chlamydia, has antibacterial effects on some Gram-negative bacteria, and also has good antibacterial effects on Toxoplasma gondii, Legionella, etc. [Wang Yiguang et al., "Bitespiramycin and its application in anti-infective diseases", December 23, 2003, Chinese invention patent: ZL 2003 1 0122420.9]. Colimycin has good tissue permeability, its in vivo antibacterial activity is significantly better than in vitro, and it has potential immunomodulatory effects. Through Phase I, II, and III clinical studies, it has been proven that colimycin is an antibiotic with safe use and significant efficacy. Our laboratory further explores the potential efficacy of colimycin and expands the clinical indications and scope of use of colimycin. Summary of the Invention: The object of the present invention is to provide a series of detection experimental studies on the activity of colimycin against clinically isolated Mycobacterium tuberculosis to prove its possible new use for treating diseases caused by Mycobacterium tuberculosis infection. The main steps of the present invention are to use the absolute concentration method to determine the anti-tuberculosis activity of corimycin on clinically isolated tuberculosis bacteria, and use isoniazid and rifampicin, the first-line anti-tuberculosis drugs used clinically, as controls. The experimental results show that corimycin shows activity against 172 strains of 240 clinically isolated tuberculosis mycobacteria, with a total effective rate of 71.66%, of which 37 strains have better activity than isoniazid, accounting for 21.5% of the effective bacteria; 39 strains have better activity than rifampicin, accounting for 22.7% of the effective bacteria; and 23 strains have better activity than both, accounting for 13.4% of the effective bacteria. The results of the present invention suggest that corimycin is expected to explore new uses in the treatment of tuberculosis infections resistant to isoniazid and rifampicin. The present invention also provides the use of a composition comprising carrimycin as an effective ingredient and a pharmaceutically acceptable carrier in the preparation of an anti-tuberculosis infection drug. The application of the present invention can be in the form of an oral dosage form, an injection dosage form or any other suitable dosage form. Implementation plan: The following examples are only intended to help those skilled in the art better understand the present invention, but are not intended to limit the present invention in any way. In a specific embodiment, the first-line anti-tuberculosis drugs commonly used in clinical practice were used as controls. A series of studies on the determination of the activity of chloramphenicol against mycobacterium tuberculosis have shown that the effective number of chloramphenicol against clinically isolated mycobacterium tuberculosis strains is better than that of the control group. It is used in the treatment of certain drug-resistant mycobacterium tuberculosis infection diseases. Example 1: Acquisition and processing of Mycobacterium tuberculosis specimens According to the provisions of the national standard WS288-2008 "Diagnostic Standards for Pulmonary Tuberculosis" issued by the Ministry of Health, select patients with clinical symptoms, signs and chest imaging examinations who are confirmed or highly suspected of tuberculosis. Collect about 2 mL of sputum, pleural effusion, cerebrospinal fluid, and pus specimens from the selected patients and add them to a 50 mL centrifuge tube with a screw cap. Add an equal amount of N-acetyl-L-cysteine ​​sodium hydroxide (NaOH-NALC) pretreatment solution to the specimen and vortex for 20 seconds. Let stand at room temperature for 18 minutes. Add PBS (pH6.8) to 40 mL, centrifuge at 3000g for 20 minutes, then discard the supernatant and keep the precipitate. Add 2 mL of PBS (pH6.8) to prepare a suspension. The treated specimen is inoculated with culture medium for solid culture. Example 2: Isolation, culture and identification of Mycobacterium tuberculosis specimens 1. Preparation of culture medium: The composition of the culture medium is shown in Table 1. Each component is added to distilled water according to the listed dosage and fully dissolved; boil for 30 minutes or autoclave at 121°C for 15 minutes. Take fresh chicken eggs, wash them with tap water, scrub them clean with soapy water, wipe and disinfect them with 75% alcohol after drying. Under aseptic operation, pour the egg liquid into a sterilized graduated enamel cup, stir well, filter with sterilized gauze, add 1000 mL and mix well; add 20 mL of 2% malachite green and mix well; dispense into test tubes (18 mm × 180 mm), add 7 mL of culture medium, and place in a steam incubator at 85 °C for 50 minutes to solidify. Take 5% of the prepared culture medium in tubes, place in an incubator at 37 °C for 48 hours for sterility test; after passing the sterility test, store in a refrigerator at 4 °C for standby and use within one month. Table 1 Culture Medium 2. Inoculation and culture of Mycobacterium tuberculosis: Absorb 0.1 mL of the specimen processed in "Example 1". Uniformly inoculate it on the inclined surface of the culture medium, and the suspension should cover the entire inclined surface. Place it in an incubator at 37 °C for culture. Observe the bacterial growth on the 3rd day and the 7th day, and then observe once a week. However, if any positive suspects are found, they should be picked out in time and observed every day. Positive growth must be verified by smear staining. If no bacterial growth is seen after culturing for 8 weeks, it is negative for Mycobacterium tuberculosis culture. 3. Acid-fast staining of Mycobacterium tuberculosis Take a little of the positive bacterial colonies of Mycobacterium tuberculosis culture obtained above, evenly coat them on a glass slide, fix them on the flame, stain them with carbol fuchsin solution, heat on the flame for 5 minutes, decolorize with 3% hydrochloric acid alcohol for about 1 minute, wash with water, then counterstain with alkaline methylene blue solution for 1 minute, wash with water, absorb the moisture, and observe under an oil immersion microscope. Those stained red are Mycobacterium tuberculosis. "Example 3" Activity Experiment of Keliamycin Against Mycobacterium tuberculosis 1. Absolute concentration method 1) Anti-tuberculosis drugs Keliamycin reference standard: sourced from the National Institute for the Control of Pharmaceutical and Biological Products, China; control drugs: isoniazid and rifampicin use reference standards from Sigma Company. The anti-tuberculosis drugs are prepared into stock solutions at certain concentrations, and then added in certain amounts to the culture medium to prepare the required doses (Table 2). 2) Strain inoculation The strains isolated from clinical specimens, the cultures confirmed as acid-fast bacteria by smear, are diluted with physiological saline containing 10% Tween 80, compared with a McFarland standard turbidity tube (Guangdong Huankai Microbial Science and Technology Co., Ltd.) to prepare a 10 -2 mg / mL bacterial solution, and inoculated into the culture medium containing the test drugs. Each batch of tests is set with negative and positive controls. The negative control is the culture medium without drugs. The positive control is the standard strain H37Rv of Mycobacterium tuberculosis. The inoculation amount per tube is 0.1 mL. The inoculated culture medium is placed in an incubator at 37 °C for culture. Table 2 Dosage of antituberculosis drugs added to the culture medium Note: The dosage of first-line drugs in the experiments of the present invention was designed according to the actual clinical dosage. 3) Result observation and determination Observe once on the 3rd day after inoculation of the bacterial solution, and then observe once a week. Report the results after 4 weeks. The culture results are determined according to the following criteria: ① If no colonies grow after 8 weeks of culture, report Mycobacterium culture negative (-); ② If there are less than 20 colonies growing on the inclined surface of the culture medium, report Mycobacterium positive and the number of colonies; ③ If the colonies on the inclined surface of the culture medium grow dispersedly and the number of colonies is more than 20, occupying less than 1 / 4 of the inclined surface area, report Mycobacterium positive (1+); ④ If the colonies on the inclined surface of the culture medium grow dispersedly, occupying more than 1 / 4 and less than 1 / 2 of the inclined surface, report Mycobacterium culture positive (2+); ⑤ If the colonies on the inclined surface of the culture medium grow densely or partially fuse, occupying more than 1 / 2 and less than 3 / 4 of the inclined surface, report Mycobacterium positive (3+); ⑥ If the colonies on the inclined surface of the culture medium grow densely, occupying more than 3 / 4 of the inclined surface area, report Mycobacterium positive (4+). 2. Activity of clarithromycin against Mycobacterium tuberculosis 1) Clinically isolated Mycobacterium tuberculosis sensitive to clarithromycin Among 240 clinically isolated and identified Mycobacterium tuberculosis strains, 172 strains were sensitive to clarithromycin at 1 or 20 (μg / ml) (Table 3). As can be seen from Table 3, among the 172 sensitive strains clinically isolated, the sensitivity of 92 strains was equivalent to that of the laboratory quality control strain H37Rv, accounting for 53.48% of the effective strains; the sensitivity of the other 80 strains was significantly higher than that of the laboratory quality control strain; 54 strains were sensitive to clarithromycin at 1 μg / ml, accounting for 31.39% of the total effective bacteria. This shows that clarithromycin has good activity against clinically isolated Mycobacterium tuberculosis. Table 3 Clinically isolated Mycobacterium tuberculosis sensitive to clarithromycin Quality control: Use the laboratory standard strain H37Rv of Mycobacterium tuberculosis as the positive control; Control: Culture medium without drugs. All isolated strains grew as 4+ in the drug-free culture medium. 2) Comparison of the activities of clarithromycin and isoniazid against some clinically isolated Mycobacterium tuberculosis The activity of kirromycin against clinical Mycobacterium tuberculosis was compared with that of isoniazid, a first-line anti-tuberculosis drug. The results showed that kirromycin at 20 μg / ml was effective against 37 strains of isoniazid-resistant clinical Mycobacterium tuberculosis (Table 4). Table 4 Comparison of the sensitivity of kirromycin and isoniazid against clinical Mycobacterium tuberculosis 3) Comparison of the activity of kirromycin and rifampicin against some clinical Mycobacterium tuberculosis The activity of kirromycin against clinically isolated Mycobacterium tuberculosis was compared with that of rifampicin, a first-line anti-tuberculosis drug. The experimental results showed that kirromycin at 20 μg / ml was effective against 39 strains of rifampicin-resistant clinical Mycobacterium tuberculosis (Table 5). Table 5 Comparison of the sensitivity of kirromycin and rifampicin against clinical Mycobacterium tuberculosis The activity of kirromycin against some clinical Mycobacterium tuberculosis was superior to that of rifampicin at 250 μg / ml. 4) Comparison of the activity of kirromycin against some isoniazid- and rifampicin-resistant clinical Mycobacterium tuberculosis The activity of kirromycin was compared with that of isoniazid- and rifampicin-resistant clinical Mycobacterium tuberculosis. The experimental results showed that kirromycin at 20 μg / ml had superior activity against 23 strains of clinical Mycobacterium tuberculosis compared with 1 μg / ml isoniazid and 250 μg / ml rifampicin (Table 6). Table 6 Comparison of the activity of kirromycin against some isoniazid- and rifampicin-resistant clinical Mycobacterium tuberculosis The experimental results of the present invention showed that kirromycin was not only active against isoniazid- and rifampicin-sensitive bacteria, the first-line anti-tuberculosis drugs, but also active against some isoniazid- and rifampicin-resistant bacteria, and was expected to find new applications in the clinical treatment of drug-resistant Mycobacterium tuberculosis infections.

Claims

1. Use of clarithromycin in the preparation of a medicament for treating Mycobacterium tuberculosis infection.

2. Use of a composition comprising clarithromycin as an active ingredient and a pharmaceutically acceptable carrier in the preparation of a medicament for treating Mycobacterium tuberculosis infection.

3. The use according to claim 1 or 2, characterized in that The clarithromycin or the composition of clarithromycin for treating Mycobacterium tuberculosis infection is prepared into an oral dosage form, an injection dosage form or any other suitable dosage form.

4. A method for treating Mycobacterium tuberculosis infection, comprising administering an effective amount of clarithromycin to a patient.

5. A method for treating Mycobacterium tuberculosis infection, comprising administering an effective amount of a composition comprising clarithromycin and a pharmaceutically acceptable carrier to a patient.

6. The method according to claim 4 or 5, characterized in that The clarithromycin or the composition of clarithromycin for treating Mycobacterium tuberculosis infection is prepared into an oral dosage form, an injection dosage form or any other suitable dosage form.